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Abstract
Background: Substantial data indicate that the oncogene microRNA 21 (miR-21) is significantly elevated in
glioblastoma multiforme (GBM) and regulates multiple genes associated with cancer cell proliferation, apoptosis,
and invasiveness. Thus, miR-21 can theoretically become a target to enhance the chemotherapeutic effect in
cancer therapy. So far, the effect of downregulating miR-21 to enhance the chemotherapeutic effect to taxol has
not been studied in human GBM.
Methods: Human glioblastoma U251 (PTEN-mutant) and LN229 (PTEN wild-type) cells were treated with taxol
and the miR-21 inhibitor (in a poly (amidoamine) (PAMAM) dendrimer), alone or in combination. The 50%
inhibitory concentration and cell viability were determined by the MTT assay. The mechanism between the miR-
21 inhibitor and the anticancer drug taxol was analyzed using the Zheng-Jun Jin method. Annexin V/PI staining
was performed, and apoptosis and the cell cycle were evaluated by flow cytometry analysis. Expression of miR-
21 was investigated by RT-PCR, and western blotting was performed to evaluate malignancy related protein
alteration.
Results: IC(50) values were dramatically decreased in cells treated with miR-21 inhibitor combine with taxol, to a
greater extent than those treated with taxol alone. Furthermore, the miR-21 inhibitor significantly enhanced
apoptosis in both U251 cells and LN229 cells, and cell invasiveness was obviously weakened. Interestingly, the
above data suggested that in both the PTEN mutant and the wild-type GBM cells, miR-21 blockage increased
the chemosensitivity to taxol. It is worth noting that the miR-21 inhibitor additively interacted with taxol on
U251cells and synergistically on LN229 cells. Thus, the miR-21 inhibitor might interrupt the activity of EGFR
pathways, independently of PTEN status. Meanwhile, the expression of STAT3 and p-STAT3 decreased to
relatively low levels after miR-21 inhibitor and taxol treatment. The data strongly suggested that a regulatory
loop between miR-21 and STAT3 might provide an insight into the mechanism of modulating EGFR/STAT3
signaling.
Conclusions: Taken together, the miR-21 inhibitor could enhance the chemo-sensitivity of human glioblastoma
cells to taxol. A combination of miR-21 inhibitor and taxol could be an effective therapeutic strategy for controlling
the growth of GBM by inhibiting STAT3 expression and phosphorylation.
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Background
Glioblastoma multiforme (GBM) is the most malignant
form of human astrocytoma [1] and the median survi-
val of GBM has remained less than one year over the
past decade. Phosphates and tensin homolog (PTEN)
located on chromosome ten, which encodes a cytoplas-
mic enzyme with both protein and lipid phosphates
activity, is mutated, decreased or not expressed at
chromosome 10q23 in 20~40% of malignant glioblasto-
mas [2]. Loss of function PTEN leads to Akt activation
by PI3K phosphorylation and results in poor prognosis
of GBM [3,4]. Downstream activated Akt is associated
with the RTKs (receptor tyrosine kinases), which
include EGFR, IGFR, and VEGFR. These activated
components of RTK pathways could further promote
cell survival and anti-apoptotic reactions through
phosphorylation and inactivation of downstream fac-
tors [5-7]. Thus, PTEN is a key checkpoint in the Akt
signaling pathway and its dysfunction triggers RTKs-
dependent oncogenesis.
Chemotherapeutic drugs are fundamental in cancer
management and are responsible for most cases of adju-
vant treatment in patients with GBMs after surgical proce-
dures. Recently, much attention has been focused on the
use taxol on glioma, both in experimental studies and in
clinical trails [8]. However, the median overall survival did
not increase in patients treated by concurrent chemora-
diotherapy. Consequently, further studies that could
enhance the therapeutic effect of taxol should be
encouraged.
MicroRNAs (miRNAs), a newly discovered family of
genes encoding small RNA molecules which bind
through partial sequence homology to the 3’-untrans-
lated regions (3’-UTRs) of target genes, play key roles in
the regulation of gene expression [9]. Due to this unique
feature, a single miRNA has multiple targets. Previous
studies have shown that miRNA expression profiles pro-
vide valuable molecular signatures for different tissues
and human cancers. Recent reports have identified miR-
21 as the only miRNA that is overexpressed in nine
types of solid tumors [10]. Accumulating evidence indi-
cates that downregulation of miR-21 in glioblastoma
cells leads to deregulation of these pathways, causing
repression of growth, increased apoptosis, and cell cycle
arrest, all of which could theoretically enhance the che-
motherapeutic effects of cancer therapy [11].
In this study, we aimed to explore whether downregu-
lating miR-21 could enhance the chemotherapeutic
effect of taxol on human glioblastoma U251 (PTEN-
mutant) and LN229 (PTEN wild-type) cells, using a poly
(amidoamine) (PAMAM) dendrimer delivery system.
PAMAM was employed as a carrier to deliver an miR-
21 inhibitor to human glioblastoma cells to investigate
the chemo-sensitivity of human glioblastoma U251
(PTEN-mutant) and LN229 (PTEN wild-type) cells to
taxol. The 50% inhibitory concentration (IC(50)) values
of taxol, determined by the MTT assay, were dramati-
cally decreased in the cells transfected with the miR-21
inhibitor. It is worth noting that the miR-21 inhibitor
additively interacted with taxol on U251cells and syner-
gistically on LN229 cells. Furthermore, the miR-21 inhi-
bitor significantly enhanced apoptosis in both U251 cells
and LN229 cells and the invasiveness of the cells was
obviously weakened compared with the single taxol che-
motherapy or miR-21 inhibitor gene therapy. The cell
cycle was arrested in G0/G1 and S phase.
Interestingly, the above data suggested that in both the
PTEN mutant and wild-type GBM cells, miR-21 block-
age increased the chemosensitivity to taxol. Thus, the
miR-21 inhibitor might interrupt the activity of EGFR
pathways, independent of PTEN status. Taken together,
a combination of the miR-21 inhibitor and taxol could
be an effective therapeutic strategy for suppressing the
growth of GBM, independently of PTEN status.
Methods
Materials and Reagent
Human glioblastoma cell lines U251 and LN229 were
obtained from the China Academia Sinica cell reposi-
tory, (Shanghai, China). We obtained antibodies from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). The
methanolic solution of PAMAM dendrimer (generation
five) containing 128 surface amino groups (G5-
PAMAM, G5D), and fluorescein isothiocyanate (FITC)
were purchased from Sigma-Aldrich (St. Louis, MO).
Semisynthetic taxol (T7191) was provided by Sigma-
Aldrich (St. Louis, MO). The 2’-O-methyl (2’-OMe-)
miR-21 inhibitors were chemically synthesized by
Shanghai GenePharma (Shanghai, China). 2’-O-Me oli-
gos were composed entirely of 2’-O-methyl bases and
had the following sequences: miR-21 inhibitor: 5’-GTC
CAC TCT TGT CCT CAA TG-3’; scrambled sequences
were 5’-AAG GCA AGC UGA CCC UGA AGU-3’. The
oligonucleotides were purified by a high-pressure liquid
chromatography system, dissolved in diethylpyrocarbo-
nate (DEPC) water, and frozen at -20°C.
Cell Culture and transfection
The cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco, USA) supplemented
with 10% fetal bovine serum (Gibco, USA), 2 mM gluta-
mine (Sigma, USA), 100 units of penicillin/ml (Sigma,
USA), and 100 μg of streptomycin/ml (Sigma, USA),
and incubated at 37°C with 5% CO2. Cells were seeded
in 75-cm2 flasks and incubated at 37°C in a fully humi-
dified atmosphere with 5% CO2. Once the cells were
80% confluent, they were starved in DMEM with 1%
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FBS for 24 h and maintained in this low serum condi-
tion for the course of all treatments.
The G5 PAMAM dendrimers were first dialyzed
against PBS (M.W. cut off 7000) for one day and then
against deionized water for another day to remove the
methanol. The miR-21 inhibitor solution (20 μmol/L)
was incubated with G5-PAMAM solution as previously
described [12]. For the combination treatment, cells
were incubated with the inhibitor prior to the addition
of taxol.
RNA extraction and real-time PCR
The miRNA was isolated 72 hours after transfection
with Ambion mirVana™ miRNA isolation kit (Ambion,
USA). A nanodrop spectrophotometer (Gene, USA) was
used to detect the concentration of total miRNA.
Reverse transcription (RT) was conducted with the mir-
Vana™ qRT-PCR miRNA detection kit (Ambion, USA)
in a 10 μl reaction system, comprising 2 μl mirVana™
5×RT buffer, 1 μl mirVana™ 1×RT primer, 25 ng total
miRNA, 0.4 μl ArrayScript™ enzyme mix, and DDW
(Deuterium Depleted Water) up to 10 μl. The RT reac-
tion was performed at 37°C for 30 min and then 95°C
for 10 min. Real-time PCR was carried out with the mir-
Vana™ qRT-PCR miRNA detection kit (Ambion, USA)
in 15 μl reaction: 2 μl mirVana™ 5×PCR buffer, 0.5 μl
50×ROX reference dye (Invitrogen, USA), 0.2 μl Super-
Taq, 0.5 μl mirVana PCR primer (Ambion, USA), and
DDW up to 15 μl. The amplification reaction was per-
formed using MJ-real time PCR (BioRad, USA) and the
protocol was performed for 40 cycles, comprising 95°C
for 3 min, 95°C for 15 sec, 60°C for 30 sec. Both RT
and PCR primers were purchased from Ambion. 5S was
used for normalization. Relative quantification was con-
ducted using amplification efficiencies derived from
cDNA standard curves. Data were shown as fold change
(2-ΔΔCt) and analyzed initially using Opticon Monitor
Analysis Software V2.02 software (MJ Research, USA).
Protein extraction and Western blotting
After the treatments, cells were lysed in a buffer com-
posed of 50 mM Tris-HCl, pH 7.4, 0.1 mM phenyl-
methylsulfonyl fluoride (PMSF), and 5 mM EGTA for
extraction of cellular proteins. The concentration of
total proteins was determined colorimetrically using
Coomassie-Plus protein assay reagent (Pierce, Rockford,
IL, USA). The samples were mixed with an equal
volume of 2× loading buffer [125 mM Tris-HCl, pH 6.8,
4% sodium dodecyl sulfate (SDS), 20% glycerol, 200 mM
1,4-dithio-dl-threitol (DTT), and 0.02% bromophenol
blue], boiled for 5 min, and loaded (40 μg/lane) onto a
10% gradient gel for SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE). After SDS-PAGE, the gels were
blotted onto Immunobilon-P nylon membrane. The
blots were blocked in 5% non-fat milk, 0.1% Tween,
Tris-HCl, pH 7.8, for two hours at room temperature.
The blots were then incubated with a specific primary
IgG antibody for two hours at room temperature or
overnight in a cold room, followed by alkaline horserad-
ish peroxidase-conjugated secondary IgG antibody for
one hour. Blots were developed using the enhanced che-
miluminescence (ECL) reagents (Amersham Pharmacia,
Buckinghamshire, UK) and visualized using the Gene-
Genius Imaging System (Syngene, Frederick, MD,USA).
Cell viability assay
The cell viability was determined by the MTT (3- (4, 5-
dimethylthiazole)-2, 5- diphenyltetrazoliumbromide)
assay. Briefly, 104 cells/well were seeded in 96-well
plates and allowed to attach overnight. The concentra-
tions of free-taxol and miR-21 inhibitor were 6 mg/L
and 20 μmol/L, respectively. The Scr-Oligo transfected
cells were set as negative controls. Each group contained
eight wells. On each day of five consecutive days, 20 μL
of MTT (0.5 mg/mL) was added to each well and the
cells were incubated at 37°C for 4 h. The reaction was
then stopped by lysing the cells with 200 μL of dimethyl
sulfoxide (DMSO) for 15 min. Quantification measure-
ments (optical density) were obtained at a wavelength of
570 nm using spectrophotometric analysis. IC50 values
were calculated from the linear regression line of the
plot of percentage inhibition versus log inhibitor
concentration.
Cell Cycle Analysis
For cell cycle analysis by FCM (flow cytometry), trans-
fected and control cells in the log phase of growth were
harvested, washed with PBS, fixed with 90% ethanol
overnight at 4°C, and then incubated with RNase at 37°
C for 30 min. The nuclei of cells were stained with pro-
pidium iodide for an additional 30 min. A total of 104
nuclei were examined in a FACS Calibur flow-cytometer
(Becton Dickinson, USA). Samples were analyzed by
flow cytometry for the FL-2 area and DNA histograms
were analyzed by Modifit software. Experiments were
performed in triplicate. Results were presented as % of
cell in a particular phase.
Evaluation of cell apoptosis
To quantify drug-induced apoptosis, annexin V/PI stain-
ing was performed, and apoptosis was evaluated by flow
cytometry analysis. Briefly, after treatment with the
miR-21 inhibitor and the drug, both floating and
attached cells were collected and subjected to annexin
V/PI staining using an annexin V-FITC Apoptosis
Detection Kit (BioVision, Palo Alto, CA), according to
the manufacturer’s protocol. The resulting fluorescence
was measured by flow cytometry using a FACS flow cyt-
ometer (Becton Dickinson, San Jose, CA).
Cell invasion assessment
Cell invasion abilities were examined using six-well
transwell chambers and a reconstituted extracellular
matrix membrane (Matrigel, USA). The cell invasion
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chambers were prepared by placing 100 μL of a 1:5 dilu-
tion of Matrigel onto the filter, and incubating the filter
at 37°C for 30 minutes to allow Matrigel polymerization.
Cells treated with free taxol, the miR-21 inhibitor or
monk (scrambled sequences), or transfected by
PAMAM or the miR-21 inhibitor combined with taxol,
were removed from the culture flasks and resuspended
at 5×105 cells/mL in serum-free medium. Two milliliters
of each cell suspension was added to the upper cham-
bers. The chambers were incubated for 48 h at 37°C in
a humid atmosphere of 5% CO2/95% air. The filters
were then fixed in 95% ethanol and stained with hema-
toxylin. The upper surfaces of the filters were scraped
twice with cotton swabs to remove non-migrated cells.
The experiments were repeated in triplicate wells, and
the migrated cells were counted microscopically (400×)
in five different fields per filter.
Analysis of the combination effect between miR-21
inhibitor and anticancer drug
To analyze the combination effect between the miR-21
inhibitor and the anticancer drug taxol, the Zheng-Jun
Jin method [13] was used. This method provides a “Q”
value, according to which the combination effect
between two drugs can be classified as an antagonistic
effect (Q<0.85), an additive effect (0.85<Q<1.15), or a
synergistic effect (Q>1.15). The formula is Q = Ea+b/(Ea
+Eb-Ea×Eb), where Ea+b, Ea and Eb are the average
effect of the combination treatment, the effect of the
miR-21 inhibitor only, and the effect of taxol only,
respectively.
Statistical analysis
Results were analyzed using SPSS software 11.0 and
compared using one-way analysis of variance (ANOVA)
with Fisher’s post hoc test. Data were presented as
mean ± standard deviation (SD) of separate experiments
(n ≥ 3). P values less than 0.05 were considered to be
significant.
Results
miR-21 expression in U251 and LN229 cells treated with
combination therapy
(2’-OMe-) antisense oligonucleotides were reported to
knockdown miR-21 expression in human glioblastoma
cells [14]. Regulation of miR-21 by the inhibitor was
verified by RT-PCR, as shown in Fig.1. Transfection of
the miR-21 inhibitor altered mir-21 levels relative to
the control by 9.4-fold and 8.5-fold in U251 and
LN229 glioblastoma cells, respectively. Interestingly,
taxol alone also downregulated miR-21 expression. In
both LN229 and U251 glioblastoma cells, the lowest
level of miR-21 expression was achieved by treatment
with the miR-21 inhibitor in combination with taxol
therapy.
miR-21 inhibitor increases the cytotoxicity of taxol on
both U251 and LN229 cells
For each experiment, dose-response curves were per-
formed for each single chemotherapeutic drug and in
combination with the miR-21 inhibitor. The result indi-
cated that the miR-21 inhibitor can decrease the prolif-
eration of both U251 and LN229 cells and increase the
cells’ sensitivity to taxol treatment. Fig 2A shows that
the taxol concentration causing 50% growth inhibition
(IC50) of U251 cells is 400 nmol/mL; whereas, in com-
bination with the miR-21 inhibitor (20 μmol/L) the
IC50 was 60 nmol/mL. Taxol can also increase the effi-
cacy of the miR-21 inhibitor. For example, combination
treatment reduced cell viability to 20% compared with
86% viability for miR-21 inhibitor gene therapy alone. In
LN229 cells, combination treatment with 20 μmol/L of
the miR-21 inhibitor reduced the IC50 of taxol from
820 to 160 nmol/L (Fig 2B). Analysis with SPSS software
demonstrates statistically significant differences between
any of the single drug treatments and the combination
treatment, as indicated on Fig 2 (P < 0.01).
To evaluate the synergistic effect of miR-21 inhibitor-
Loaded PAMAM with taxol on cell growth, we used the
MTT assay to compare the growth of U251 and LN229
cells transfected with miR-21 inhibitor alone or with
taxol. The measurements were made 72 h after transfec-
tion. The data (from triplicate samples) were analyzed
for differences by unpaired, two-tailed t test. As indi-
cated, taxol alone exhibited a moderate suppressive
effect in the first three days of the MTT assay, resulting
in maximal inhibition of 87% in U251 (Fig.2C), and 87%
in LN229 glioblastoma cells (Fig. 2D). MiR-21 inhibitor-
PAMAM complexes appeared to show better suppres-
sive effects during the first three days of the MTT assay,
however, combined treatment with the miR-21 inhibitor
and taxol yielded a better effect on tumor growth sup-
pression effect in the MTT assay, but the survival rate
of both cells was still more than 60% on the sixth day of
the MTT assay. Co-delivery of miR-21 inhibitor and
taxol always maintained the best suppression effect dur-
ing the entire MTT assay and resulted in maximal inhi-
bition of 35% and 43% at 48 hours in U251 and LN229
glioblastoma cells, respectively.
miR-21 inhibitor additively interacts with taxol on
U251cells and synergistically on LN229 cells
To investigate the nature of the combination effect
between the miR-21 inhibitor and the anticancer drugs
on U251 and LN229 cells, the Zheng-Jun Jin method
which was a useful approach to evaluate the combina-
tion effect among different drugs was performed to ana-
lyze the cytotoxicity data for antagonism, additivity, or
synergy after cells are treated for three days. The Q
value for LN229 cells was 1.32, indicating that
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synergistic effects appeared for the combination of the
miR-21 inhibitor with taxol. On the other hand, the Q
value for U251 cells was 0.97, indicating that the cyto-
toxicity data show additive effects after the cells were
treated with the combination of the miR-21 inhibitor
with taxol.
Activities of the AKT pathway in human glioblastoma
LN229 and U251 cell lines
Activation of the AKT pathway in malignant cells con-
tributes to survival signaling [15]. We first examined
the levels of phosphor-AKT expression in LN229 and
U251 cells after treatment with the miR-21 inhibitor
combination with taxol therapy (Fig. 3). The protein
level determined by western blotting demonstrated
that treatment of both LN229 and U251 cells with
miR-21 inhibitor and taxol combination therapy could
dramatically reduced the expression of phosphorylated
Akt (p-Akt) significantly (P < 0.01) compared with
either single taxol chemo-therapy or miR-21 inhibitor
therapy alone.
And then we would like to further explore the effects
of the miR-21 inhibitor and taxol on the key members
of the AKT pathway. Overexpression of the gene encod-
ing the epidermal growth factor receptor (EGFR) occurs
commonly in glioblastoma, leading to activation of
downstream kinases including phosphatidylinositol 3’-
kinase (PI3K) and signal transducer and activator of
transcription 3 (STAT3). Fig 4 shows Western blots for
PTEN, a direct target of mir-21; EGFR, an initiator of
the EGFR pathway; and STAT3 and phosphorylated
STAT3, a nuclei co-factor of EGFR involved in cell-
cycle progression and anti-apoptosis [16]. Actin was
used as the control. Transfection of LN229 and
U251cells with the miR-21 inhibitor or free taxol alone,
caused varying degrees of increase in PTEN-related
bands, reaching an approximately 5-fold increase for the
miR-21 inhibitor and taxol combination treatment
group. There is slight change in the protein level of
EGFR in taxol treatment cells, on the contrast, 4.2-fold
and 3.9-fold reduction was seen in combination therapy
treated LN229 and U251 cells respectively... In addition,
combination therapy also caused the notably down-reg-
ulation expression of both STAT3 and p-STAT3 com-
pare to the both single treatment. U251 harbors the
mutant form of PTEN, the direct target of miR-21; thus
the data implies that miR-21 or taxol could be involved,
in part, in the activities of EGFR pathways indepen-
dently of PTEN status.
Figure 1 Real time PCR analysis of miR-21 expression in glioblastoma cells treated with taxol and miR-21 inhibitor, alone or
combination. RT-PCR results showing significant knockdown of miR-21 expression in U251 and LN229 cells.
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miR-21 inhibitor and taxol induced apoptosis
FACS analysis was performed to detect DNA fragmenta-
tion in apoptotic cells following combined use of miR-
21 inhibitor and taxol in U251 and LN229 human brain
cancer cells (Fig. 5A). Untreated cells served as a nega-
tive control. Percentages of apoptotic cells are shown in
the histogram (Fig. 5B). Compared with single taxol
(6.24% and 6.25%, respectively) and miR-21 inhibitor
(21.75% and 18.74%, respectively) treatment in U251
and LN229 cells, the combination of the miR-21 inhibi-
tor and taxol therapy caused a significant (p < 0.05)
increase amount (24.68% and 21.97%, respectively) of
apoptotic death, suggesting that an additive induction of
apoptosis developed in the cells co-infected with the
miR-21 inhibitor and taxol.
Si et al [17] recently showed the knockdown of miR-
21 inhibited tumor cell growth in vitro and in vivo by
effecting an increase in apoptosis associated with down-
regulation of Bcl-2 expression, a potent anti-apoptotic
regulatory factor. Preclinical studies have shown that
ectopic expression of Bcl-2 confers resistance to several
chemotherapeutic agents, including taxol [18]. In the
current study, a significant decrease in the expression of
Bcl-2 can be observed after treatment with taxol com-
bined with the miR-21 inhibitor in U251 and LN229
cells (Fig.5C). The protein level of BcL-2 revealed an
approximately 6-fold reduction in the miR-21 inhibitor
alone treated cells, and an approximately 7.5-fold reduc-
tion in cells treated with the combination.
The in vitro sequence-specific functional inhibition of
miR-21 in glioma cells leads to increased caspase levels,
followed by cell death. Both miR-21 knockdown and
taxol treatment alone depressed viability and caused cas-
pase-3 upregulation in both cell lines, implicating apop-
tosis to be involved as a cell death mechanism [19].
However, marked additional caspase-3-associated cell
death was observed for the combined treatment (P <
0.005). These findings indicate that, at least in vitro,
knockdown of miR-21 before taxol administration sensi-
tizes glioma cells for taxol cytotoxicity.
Figure 2 Effect of the miR-21 inhibitor on the chemo-sensitivity of U251 and LN229 cells to taxol treatment. The growth of U251 (Figure
2a) and LN229 (Figure 2b) cells were inhibited by the miR-21 inhibitor, taxol only, and the indicated combinations. The cells were treated with
the miR-21 inhibitor complexed to PAMAM for 6 h at 37°C. The medium was then replaced with media containing various concentrations of
taxol. After 72 h of incubation, an MTT assay was performed. Absorbance at 570 nm was normalized to the control (untreated cells) to
determine cell viability. Each value represents the mean ±SD from triplicate determinations. An aqueous solution of taxol (circles) and miR-21
inhibitor-loaded PAMAM (triangle) was incubated with human glioblastoma U251 (Figure 2c) and LN229 (Figure 2d) cells for six days. Drug-
induced decrease in cell numbers was measured using the MTT assay. Values represent the mean ± SD (n = 6 replicates).
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Figure 3 Activity of the AKT pathway in human glioblastoma LN229 and U251 cell lines. Representative Western blots showing the levels
of p-AKT expression and the results of densitometric determinations. Significant differences from the control value are indicated by **p < 0.01.
Figure 4 Evaluation of the expression of PTEN, EGFR, STAT3, and p-STAT3 in human glioblastoma LN229 and U251 cell lines. Western
blot of protein extracts from cells treated with the miR-21 inhibitor or taxol, alone or combination. The expression of b-actin was examined to
ensure uniform protein loading in all lanes.
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Figure 5 The miR-21 inhibitor enhanced taxol induced apoptosis. Flow cytometry analyses of propidium iodide-stained cells were
performed in triplicate (Fig. 5A). Percentages of apoptotic cells are shown in the histogram (Fig. 5B). The effectiveness of the miR-21 inhibitor
combined with taxol on BcL-2 and caspase-3 was analyzed by western blotting, with mock cells as controls (Fig. 5C). Antibodies against b-actin
were used as a loading control to ensure uniform protein loading in all lanes.
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Synergistic effects of miR-21 inhibitor and taxol on Cell
cycle analysis
To better understand the synergistic effects on cell cycle
progression, we exposed cells to the miR-21 inhibitor
and taxol alone or in combination and evaluated
changes in the cell cycle distribution by flow cytometry
analysis (Fig.6A). Untreated cells served as negative con-
trols. Treatment with taxol resulted in an increase in
the population of cells that were in S phase. Fig.6B
shows a representative experiment in which 20.3% of
control U251 cells were in S phase, whereas taxol-trea-
ted cultures had 57.4% S-phase cells. Similarly, in Ln229
cells, taxol also caused an increase in S phase, from
22.5% to 38.2%.
Compared with control cells, the miR-21 inhibitor
substantially and consistently increased the G1 popula-
tion by 38.6% to 60.4% in U251 cells, by 48.7% to 70.1%
in LN229 cells, indicating that miR-21 functions as a
positive regulator of the G1-to-S transition. It is worth
noting that the miR-21 inhibitor combined with taxol
therapy produced both a greater percentage of G0/G1
and S phase cells, suggesting a synergistic effect of the
combination on cell cycle progression.
The passage of cells through the cell division cycle is
regulated by a family of kinases, the cyclin-dependent
kinases (CDKs) and their activating partners, the cyclins.
The G1/S phase transition is regulated primarily by D-
type cyclins (D1, D2 or D3) in complex with CDK4/
CDK6. No significantly alteration of cyclin D1 expres-
sion was observed with taxol alone (Fig.6C), suggesting
that taxol alone does not produce any marked effect in
the regulation of cell cycle in G0/G1 phase. The protein
level of cyclin D1 revealed an approximately 4.4-fold
reduction in U251 cells and a 4.2-fold decrease in
LN229 cells, for treatment with the miR-21 inhibitor
alone, and a 3.0-fold and 2.6-fold reduction, in the com-
bined treatment U251 and LN229 cells, respectively.
miR-21 inhibitor and taxol combination therapy regulate
cell invasion
To measure the effects the miR-21 inhibitor combined
with taxol on glioma cell invasiveness, a better indica-
tion of glioma migratory and invasive properties in
vitro, we employed a Transwell invasion assay. The sys-
tem consists of two fluid-filled, stacked compartments,
separated by a porous membrane filter coated with
Matrigel. Cells were grown in the upper chamber and
assessed for invasion through the Matrigel toward a
chemo-attractant (10% serum) in the lower chamber.
The number of invasive cells in cultures treated with
the combination was significantly reduced relative to the
control cells with out any treatment (Fig. 7A and 7B); a
decrease of 46 to 25 in U251 cells and 54 to 28 in
LN229 cells.
Accumulated data suggest that matrix metalloprotein
(MMP) levels and activities are significantly elevated in
human gliomas, which contributes to glioma cell inva-
sion of the surrounding normal tissues, metastasis, and
angiogenesis through cell surface ECM degradation [20].
In this respect, the levels of expression of MMP-2 and
MMP-9 proteins in U251 and LN229 cells after combi-
nation treatments were also evaluated by western blot-
ting (Fig.7C). Significantly decreased expression of
MMP-2 and MMP-9 was observed after treatment with
taxol combined with the miR-21 inhibitor in U251 and
LN229 cells.
Discussion
miR-21 inhibitor sensitizes human glioblastoma cells to
taxol
At present, cancer drug resistance is considered as a
multifactorial phenomenon involving several major
mechanisms, such as increased repair of DNA damage,
reduced apoptosis, altered metabolism of drugs, and
increased energy-dependent efflux of chemotherapeutic
drugs that diminish the ability of cytotoxic agents to
kill cancer cells [21]. MiRNA expression affecting mul-
tiple genes simultaneously, provided support for this
hypothesis. This was evidenced by (a) downregulation
of miR-451 leads to the increased metabolism of DOX
[22]; (b) downregulation of miR-328 results in
increased mitoxantrone sensitivity [23]; and (c) Over-
expression of miR-221 and miR-222 in MCF-7 cells
confers resistance to tamoxifen [24]. These finding
supported the hypothesis that correction of altered
expression of miRNA might have significant implica-
tions for therapeutic strategies aiming to overcome
cancer cell resistance.
In this study, we demonstrated for the first time that
the knockdown of miR-21 expression by a miR-21 inhi-
bitor contributed to sensitizing human glioma cells to
the anticancer drug taxol. MiR-21 was first implicated
as an anti-apoptotic factor by the observation that
knockdown of miR-21 increased apoptotic cell death in
human glioblastoma cells [14]. It has been reported that
miR-21 contributes to the malignant phenotype of
tumor cells by blocking expression of critical apoptosis-
related genes in human cancer cell lines. Despite the
well-established role of miR-21 in GBM, the molecular
mechanism of knocking down miR-21 in GBM che-
motherapy remains largely unexplored.
Our dose-response data indicated that decreasing the
miR-21 levels resulted in 6- and 5-fold increases in drug
sensitivity (IC50), respectively, between inhibitor- and
taxol-treated GBM cells. This demonstrated that the
miR-21 inhibitor resulted in an increased sensitivity of
glioma cells to taxol.
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Figure 6 miR-21 inhibitor and taxol induce G1 and S phase arrest on cell cycle distribution. U251 and LN229 cells were treated with the
miR-21 inhibitor and taxol alone or in combination, and cell cycle distributions were detected by Flow cytometry 48 h later (Fig. 6A).
Percentages of cells in different phases of the cell cycle are shown in the histogram (Fig. 6B). Western blotting showing cyclin D1 activity in
U251 and LN229 cells. (Fig. 6C) Representative Western blots showing altered levels of active cyclin D1 expression. The expression of b-actin was
examined to ensure uniform protein loading in all lanes.
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Figure 7 Effects of miR-21 inhibitor and taxol on cell invasion ability in U251 and LN229 cell lines. Cell invasion ability was assessed by a
transwell assay after 48 h treatment with the miR-21 inhibitor and taxol, alone or in combination (Fig. 7A). The numbers of cells that could
invade via the membrane are shown as a histogram (Fig. 7B). Western blotting validation of proteins (MMP-2 and MMP-9) downregulated by
miR-21 inhibitor and taxol combination therapy in both U251 and LN229 cell lines (Fig. 7C). The expression of b-actin was examined to ensure
uniform protein loading in all lanes.
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miR-21 inhibitor enhances anti-proliferation effect of
taxol to glioblastoma cells independent of PTEN status
Previous study proved that miR-21 could direct regulate
PTEN tumor suppressor gene mRNA translation at
post-transcriptional level in hepatocellular carcinoma
and GBM cells [25]. Different genetic alterations of
PTEN, including mutation, deletion, and translation
suppression, could lead to aberrant EGFR pathway acti-
vation in GBM. Maier et al also analyzed the role of
PTEN in invasion using the two highly infiltrative
glioma cell lines U87MG (lacking PTEN function) and
LN229 (PTEN wild-type) [26]. We deduced that knock-
ing down miR-21 sensitized GBM to taxol through
PTEN mRNA translation blockage.
Yet, it is worth noting that cytotoxicity data algorithm
results indicated that the miR-21 inhibitor additively
interacted with taxol on U251cells and synergistically on
LN229 cells for MTT assay and additively for Annexin
V/PI apoptosis assay in both GBM cell lines. Interest-
ingly, the data of miR-21 inhibitor suppressed U251
GBM growth indicated there was an independent PTEN
pathway although the exact mechanism was not clear.
The above data suggested that both in the PTEN
mutant and in the wild-type GBM cells, miR-21 block-
age could increase the chemo-sensitivity to taxol. Chan
et al reported that knocking down miR-21 could
increase caspase3/7 activity similarly though in LN229
and U87 GBM cell that had different PTEN background
[14]. Our previous research indicated that antisense
miR-21 ODN could induce U251 and LN229 GBM cell
apoptosis via attenuating EGFR signaling pathway.
Besides, multiple cancer cell apoptosis or metastasis
related genes including PDCD4[10], P53 signaling net-
work[11], RECK[20], S-TRAIL[27] etc were validated to
be miR-21’s function targets in both brain tumors and
other epithelium original human cancers. Presumably,
miR-21 inhibitor mediated human GBM cell apoptosis
effect in a one hit multiple target mechanism rather
than directly inhibition of PTEN mRNA translation.
Mild apoptosis induction difference of miR-21 inhibition
in U251 and LN229 GBM cell suggested, compared to
miR-21 blockage, PTEN wide-type or induction was a
fine tune in the oncogenesis of GBM. And miR-21 sup-
pression had clinical potential to enhance chemo-drug
effect of chemotherapy in GBM patient with different
PTEN genetic background.
EGFR has been a central focus of study in glioma due
to its proposed role in the transformation and growth of
glial tumors, and the fact that EGFR is the most com-
monly amplified gene in GBM. Activation of EGFR sig-
naling plays a central role in GBM. AKT is the direct
effector of EGFR downstream signaling; the expression
of phosphorylated-AKT is the key factor representing
the activities of EGFR pathways [28]. Both in U251 and
in LN229 GBM cells, the miR-21 inhibitor could sup-
press the EGFR signaling pathway activity. From the
data included in the manuscript, it’s difficult to elucidate
the exact mechanism that miR-21 inhibitor caused
EGFR suppression in both PTEN mutant and wild type
GBM. Bioinformatics analysis indicated that, EGFR
mRNA didn’t carry a miR-21 binding site (un-published
data). Thus we deduced transcription inhibition might
contribute to EGFR signaling pathway.
Knocking down miR-21 enhances chemotherapeutic effect
of taxol to glioblastoma cells via STAT3 inhibition and
dephosphorylation
PI3K-AKT, Ras, and mitogen-activated protein kinases
(MAPK), and receptor tyrosine kinases, including EGFR,
contributed strongly to the growth and promotion of
GBM. These diverse signaling pathways converge at spe-
cific transcription factors, including STAT3. STAT3 is
constitutively activated in 60% of primary high-grade/
malignant gliomas and the extent of activation correlates
positively with glioma grade. The constitutive activation
of STAT3 coexists with EGFR expression in 27.2% of
primary high-grade/malignant gliomas [29]. Activated by
EGFR or other RTKs, STAT3 proteins cooperate with
other transcription factors to regulate expression of
numerous malignancy related genes, including bcl-2,
bcl-xL, mcl-1, p21WAF1/CIP1, MMP-9, and Cyclin D1.
Stat3 was suppressed in the present study, consistent
with it being predicted to be a miR-21 target by mathe-
matic algorithm [30].
Fig. 3 shows that treatment of LN229 and U251 GBM
cells with the miR-21 inhibitor or with taxol decrease
the expression levels of EGFR, STAT3, and p-STAT3.
In addition, the expressions of BCL-2, Caspase-3, Ki67,
MMP2/9, and TIMP-1 were changed by miR-21 inhibi-
tion in U251 cell. These data can be explained by
STAT3 inhibition and dephosphorylation.
Current therapy for malignant gliomas needs to seek
novel targets and more effective, less toxic therapeutic
strategies. The results from this study provide new ratio-
nales for novel combinational therapies using an miR-21
inhibitor to synergistically cooperate with taxol in
PTEN-wt and PTEN-mutant patients. These findings
also prompt the need for future evaluation of the thera-
peutic efficacy of EGFR/STAT3-based combinational
therapy in targeting high-grade/malignant gliomas that
overexpress miR-21.
Conclusions
The above data suggested that in both the PTEN mutant
U251 cell line and the PTEN wild-type LN229 cells, miR-
21 blockage could increase the chemosensitivity to taxol.
It is worth noting that the miR-21 inhibitor additively
interacted with taxol on U251cells and synergistically on
LN229 cells. Thus, the miR-21 inhibitor might interrupt
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the activity of EGFR pathways, independently of PTEN
status. The miR-21 inhibitor enhanced the chemo-sensi-
tivity of human glioblastoma cells to taxol and a combi-
nation of the miR-21 inhibitor and taxol could be an
effective therapeutic strategy for suppressing the growth
of GBM, independent of PTEN status.
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